key: cord-0884503-kv875rwb authors: Levine, Deborah Jo; Ross, David J; Sako, Edward title: Single Center “Snapshot” Experience With Donor-Derived Cell-Free DNA After Lung Transplantation date: 2020-09-16 journal: Biomark Insights DOI: 10.1177/1177271920958704 sha: 9f24d4b2ca57ea063d8df4e62f1a84bbffd316d4 doc_id: 884503 cord_uid: kv875rwb nan Lung transplantation (LT) provides a potentially curative option for many patients suffering from a spectrum of endstage lung diseases. However, the median 5-year survival after LT remains at only 60%, notably inferior to that currently achieved with other solid organ transplants. 1 The higher mortality is primarily attributed to the prevalent complication of chronic lung allograft dysfunction (CLAD). Early detection of CLAD would allow implementation of strategies to reverse or halt further progression. Additionally, an unpredictable clinical presentation for CLAD, makes this a more challenging endeavor. Acute cellular rejection (ACR), antibody mediated rejection (ABMR), de novo donor specific HLA antibodies (DSA), auto-antibodies and infection, have all been recognized as risk factors for CLAD. [2] [3] [4] [5] [6] [7] Pulmonary function tests (PFTs), histopathology, and DSA are often required during evaluation to mitigate these risk factors. Nevertheless, conventional videobronchoscopy with biopsies may lack sufficient sensitivity and specificity for the elucidation of ACR, ABMR, and CLAD. 8 These deficiencies underscore a need for molecular diagnostics to complement what has been provided by conventional assessments. There is no more urgent time than the present with the CoVid-19 pandemic, to evaluate a non-invasive tool for surveillance of allograft quiescence and rejection. LT programs by necessity, have adjusted their post-transplant protocols to both conserve critical healthcare resources and to minimize the risk of exposure to these vulnerable patients. Surveillance bronchoscopy and formal pulmonary function tests, utilized at most centers to evaluate for early allograft dysfunction, have been deferred in order to mitigate patient contagion exposures. This decrease in clinical monitoring has created significant concern regarding a potential delay in diagnosis of rejection or allograft infection. Thus, this interruption in routine monitoring has challenged the transplant community to consider alternative methods to surveil LT patients. We endeavored to assess clinical utility of a strategy implementing biomarker surveillance with plasma donor-derived cell-free DNA (dd-cfDNA) in concert with a clinical monitoring strategy. Agbor-Enoh et al, has previously described measurement of dd-cfDNA by "shotgun" methods (that require genomic sequencing of donor and recipient) with an elevation during lung acute cellular and antibody-mediated allograft rejection. 9,10 Therefore, we performed, a "Snapshot" investigation implementing a clinical-grade "next generation sequencing" (NGS) dd-cfDNA assay (AlloSure ® ) that interrogates a panel of single nucleotide polymorphisms (SNPs) across all 22 somatic chromosomes without requirement for prior genotyping. This dd-cfDNA assay, with a detectable range for donor (allograft) cell-free DNA fraction of 0.12% to 16.0%, has been previously validated in in large multi-center studies for kidney and heart transplantation. [11] [12] [13] [14] This assay specifically does not require separate donor genomic material and is provided with rapid turn-around time for results (<72 hours) from a Central Clinical Laboratory Improvements Act (CLIA)-validated and College of American Pathologists (CAP)-accredited laboratory [CareDx, Inc.; Brisbane, CA, USA]. The study had been approved by our Institutional Review Board for Clinical Research (HSC20080378H) and informed patient consent was obtained, in anticipation of implementing a LT program surveillance strategy, which would include usual laboratory studies, dd-cfDNA, home selfspirometry assessment, and tele-health visits during the CoVid-19 pandemic. We assessed 48 unique patients, between 3-months and (Figure 2 ) and an optimal threshold for rejection was determined (maximal sensitivity + specificity) with dd-cfDNA = 0.51% whereupon sensitivity = 81% (95% CI: 58%-95%) and specificity = 100% (95% CI: 71%-100%). We conclude that low levels of dd-cfDNA (<0.20%) typically characterize stable healthy LT allografts (Figure 3) , while higher levels correlated with the spectrum of allograft rejection. The cohort with allograft infection had variability in levels of dd-cfDNA, likely due to inherent challenges in differentiation of invasive infection versus airway colonization. These results support the concept that further investigation and serial trend monitoring of dd-cfDNA, may serve valuable for assessment of LT allograft dysfunction and to preserve allograft health. DJL and DJR contributed to concept, design, and initial draft of study. All authors participated equally in implementation of study, data analysis, manuscript development, and final manuscript approval. David J Ross https://orcid.org/0000-0002-9343-9260 The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match Chronic lung allograft dysfunction: evolving concepts and therapies Validation of a post-transplant chronic lung allograft dysfunction classification system A new classification system for chronic lung allograft dysfunction The impact of allograft CXCL9 during respiratory infection on the risk of chronic lung allograft dysfunction Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation Prevalence of antibodies to lung self-antigens (Kalpha1 tubulin and collagen V) and donor specific antibodies to HLA in lung transplant recipients and implications for lung transplant outcomes: Single center experience Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies: a perspective from members of the pulmonary pathology society Late manifestation of alloantibodyassociated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients Cell-free DNA and active rejection in kidney allografts Biological variation of donor-derived cell-free DNA in renal transplant recipients Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study